#USA #Berwyn #Nordic Pharma #Dry Eye #LACRIFILL®

Introduction

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., recently announced the inclusion of their innovative product, LACRIFILL® Canalicular Gel, in the new report on managing dry eye symptoms, the Dry Eye Workshop (DEWS) III. This notable report is published by the Tear Film and Ocular Surface Society (TFOS) in the respected American Journal of Ophthalmology.

Overview of LACRIFILL® Canalicular Gel

LACRIFILL® is designed to address the prevalent symptoms associated with dry eye, making it a crucial development in ophthalmic treatments. The gel, based on cross-linked hyaluronic acid (HA), is evaluated as a novel therapy in a comprehensive review that helps busy practitioners navigate the available treatment options effectively.

DEWS III Report Highlights

Published in June 2025, the DEWS III report incorporates two significant studies regarding LACRIFILL®. The first study demonstrated positive outcomes in corneal staining, Schirmer test results, and other metrics three months after treatment, indicating a substantial improvement in patient conditions. The second study compared LACRIFILL® to a commercially available hydrogel punctal plug, revealing that the HA-based gel is both safe and well-tolerated, providing statistically significant enhancements in symptoms for up to six months.

Presentation at WIO Summer Symposium

Nordic Pharma will also present findings from their recent analyses at the Women in Ophthalmology (WIO) Summer Symposium, taking place from August 7 to 10. One highlighted study reveals that in a trial of 117 participants, 66.25% reported over a 50% decrease in symptoms after one month of LACRIFILL® treatment, with many participants noting up to a 90%-100% improvement, particularly concerning burning sensations and feelings of grit in the eyes.

Dr. Monica Patel, a key author of the study, emphasized the versatility of the gel across various patient demographics, including those with coexisting conditions such as diabetes or thyroid disease. Dr. Patel noted, “The consistent improvement metrics validate self-reported assessments as a reliable evaluation tool.”

In another endorsement, Dr. Jai Parekh, Chief Commercial Officer of Eye Care U.S., praised the study's findings, asserting that patient-reported outcomes and Ocular Surface Disease Index scores robustly support the efficacy of LACRIFILL® in mitigating dry eye symptoms.

Real-World Evidence

Clinical case studies published in reputable journals further underscore LACRIFILL®’s effectiveness. A June article in Cataract & Refractive Surgery Today detailed a case where LACRIFILL® significantly aided a patient suffering from blurred vision following cataract surgery. After other treatments failed, the administration of LACRIFILL® led to improvements in visual clarity and comfort.

In another instance reported in Modern Optometry, a patient with Demodex blepharitis and uncontrollable dry eye disease saw considerable symptomatic relief following treatment with LACRIFILL®, as their SPEED scores improved dramatically from 10/28 to 5/18, and corneal staining reduced substantially.

Corporate Background

Nordic Group B.V. is a mid-sized, private pharmaceutical enterprise focused on specialized product development and marketing. By employing targeted developments and acquisitions, Nordic aims to strengthen its position in the fields of ophthalmology, rheumatology, and women’s health. The company is well-established in Europe and is expanding its global footprint through strategic acquisitions.

Nordic Pharma, Inc. collaborates with well-established global biopharmaceutical firms and leverages its expertise in biotechnology and sterile manufacturing to introduce cutting-edge treatments in the market.

Conclusion

For further information about the LACRIFILL® Canalicular Gel or to place an order, interested parties can visit lacrifill.com. The inclusion of LACRIFILL® in the DEWS III report signifies a pivotal moment in dry eye therapy, providing hope for many suffering from this common condition.